Lonza offloads specialty ingredients unit in $4.7B sale to Bain Capital, Cinven in consolidation around biopharma

Lonza will sell its specialty ingredients business to Bain Capital and UK private equity firm Cinven for $4.67 billion as the contract manufacturer continues to consolidate its business around biopharma work and capsules, the company said Monday.